Farxiga (dapagliflozin), in tablets for oral use, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that was approved by FDA in January 2014 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Read more
#icymi
Editorial Questions? Contact the Editorial Team. Click Here.
Sales, Reprints, Classified questions? Contact the Sales Team. Click Here.
